Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03809234 · ClinicalTrials.gov registry record · Phase 1
Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT03809234 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 14 participants.
The verdict
NCT03809234, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
To determine the time-course of plasma and CSF concentrations of intravenous (IV) ondansetron in healthy subjects, with and without selective inhibition of Pgp efflux transporter.
Interventions
- DRUG Ondansetron 8mg with Saline & Tariquidar
- DRUG Ondansetron 16mg with Saline & Tariquidar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-05-20 |
| Est. Completion | 2020-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03809234
The ClinicalTrials.gov registry entry for NCT03809234 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ondansetron 8mg with Saline & Tariquidar is the first listed.
NCT03809234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03809234 about?
NCT03809234 is a clinical study titled "Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers". To determine the time-course of plasma and CSF concentrations of intravenous (IV) ondansetron in healthy subjects, with and without selective inhibition of Pgp efflux transporter.
What is the current status of trial NCT03809234?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2019-05-20. Estimated completion is 2020-11-30.
What interventions are being tested in trial NCT03809234?
The interventions under investigation include: Ondansetron 8mg with Saline & Tariquidar (DRUG), Ondansetron 16mg with Saline & Tariquidar (DRUG).
Who is sponsoring clinical trial NCT03809234?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.